Masashi Saito

Summary

Publications

  1. ncbi request reprint A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA)
    Masashi Saito
    Seta Clinic Group, Chiyoda ku, Tokyo, Japan
    Anticancer Res 33:2957-63. 2013
  2. doi request reprint Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors
    Atsutaka Noguchi
    Seta Clinic Group, Seta Clinic Tokyo, 3 6 5 Iidabashi, Chiyoda ku, Tokyo, Japan
    Cytotherapy 13:92-7. 2011

Collaborators

Detail Information

Publications2

  1. ncbi request reprint A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA)
    Masashi Saito
    Seta Clinic Group, Chiyoda ku, Tokyo, Japan
    Anticancer Res 33:2957-63. 2013
    ..Combination of ALA/DCA, hyperthermotherapy, and cellular immunotherapy may be a low-invasive palliative therapy superior in maintaining quality of life of tumor-bearing terminally ill individuals...
  2. doi request reprint Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors
    Atsutaka Noguchi
    Seta Clinic Group, Seta Clinic Tokyo, 3 6 5 Iidabashi, Chiyoda ku, Tokyo, Japan
    Cytotherapy 13:92-7. 2011
    ..Zoledronate-activated Vγ9γδ T cell-based immunotherapy that restores the number of Vγ9γδ T cells in cancer patients may provide another mode of adoptive immunotherapy...